Think Research Corporation announced its acquisition by Beedie Investments Ltd. for a cash consideration of $0.32 per share, representing a 100% and 75% premium over the closing and 30-day VWAP of shares on the TSX Venture Exchange as of February 15, 2024, respectively. This deal, excluding shares held by Beedie and other insiders, signifies Beedie Capital's confidence in Think Research's potential for growth in digital health solutions globally. The transaction was endorsed unanimously by Think's board, following a comprehensive evaluation and the advice of external advisors. It aims to provide shareholders with immediate liquidity amid market challenges and was facilitated by a special committee's recommendation, supported by a fairness opinion from Canaccord Genuity Corp. The arrangement includes a go-shop provision, allowing for the solicitation of superior proposals. Legal advisement was provided by Cassels Brock & Blackwell LLP for the special committee, Stikeman Elliott LLP for the company, and Dentons Canada LLP for Beedie Capital. The acquisition is set for completion in the second quarter of 2024, pending shareholder, court, and regulatory approvals, with a special meeting anticipated in early April 2024.